

--347. (New) A purified mature protein produced by the method comprising:

- (a) expressing a mature protein encoded by the cDNA contained in ATCC Deposit Nos. 75698 from a host cell; and
- (b) recovering said mature protein.

348. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a natural source.

349. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a recombinant host cell engineered to express the mature protein.

350. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a mammalian cell.

351. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a bacterial cell.

352. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a baculovirus cell.

353. (New) The purified mature protein of claim 347, wherein the mature protein is recovered from a yeast cell.

354. (New) The purified mature protein of claim 347, wherein the mature protein is recovered by chromatography.

355. (New) The purified mature protein of claim 347, wherein the mature protein is recovered by an antibody.

356. (New) The purified mature protein of claim 347, wherein the mature protein is a homodimer.

357. (New) The purified mature protein of claim 347, wherein the mature protein is fused to a heterologous polypeptide.

358. (New) A composition comprising the purified mature protein of claim 347 and a pharmaceutically acceptable carrier.

359. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has a wound, tissue, or bone damage.

360. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has ischemia.

361. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has had a myocardial infarction.

362. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

363. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has a wound, tissue, or bone damage.

364. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has ischemia.

365. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has had a myocardial infarction.

366. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified mature protein of claim 347, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

367. (New) A purified proprotein produced by the method comprising:

(a) expressing a proprotein encoded by the cDNA contained in ATCC Deposit Nos. 75698 from a host cell; and

(b) recovering said proprotein.

368. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a natural source.

369. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a recombinant host cell engineered to express the proprotein.

370. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a mammalian cell.

371. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a bacterial cell.

372. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a baculovirus cell.

373. (New) The purified proprotein of claim 367, wherein the proprotein is recovered from a yeast cell.

374. (New) The purified proprotein of claim 367, wherein the proprotein is recovered by chromatography.

375. (New) The purified proprotein of claim 367, wherein the proprotein is recovered by an antibody.

376. (New) The purified proprotein of claim 367, wherein the proprotein is a homodimer.

377. (New) The purified proprotein of claim 367, wherein the proprotein is fused to a heterologous polypeptide.

378. (New) A composition comprising the purified proprotein of claim 367 and a pharmaceutically acceptable carrier.

379. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has a wound, tissue, or bone damage.

B<sub>1</sub>  
380. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has ischemia.

381. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has had a myocardial infarction.

382. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

383. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has a wound, tissue, or bone damage.

384. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has ischemia.

385. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has had a myocardial infarction.

B<sub>1</sub>  
386. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified proprotein of claim 367, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

387. (New) A purified protein produced by the method comprising:

(a) expressing a protein encoded by the cDNA contained in ATCC Deposit Nos. 75698 from a host cell; and

(b) recovering said protein.

388. (New) The purified protein of claim 387, wherein the protein is recovered from a natural source.

389. (New) The purified protein of claim 387, wherein the protein is recovered from a recombinant host cell engineered to express the protein.

390. (New) The purified protein of claim 387, wherein the protein is recovered from a mammalian cell.

391. (New) The purified protein of claim 387, wherein the protein is recovered from a bacterial cell.

392. (New) The purified protein of claim 387, wherein the protein is recovered from a baculovirus cell.

393. (New) The purified protein of claim 387, wherein the protein is recovered from a yeast cell.

394. (New) The purified protein of claim 387, wherein the protein is recovered by chromatography.

395. (New) The purified protein of claim 387, wherein the protein is recovered by an antibody.

B<sub>1</sub> 396. (New) The purified protein of claim 387, wherein the protein is a homodimer.

397. (New) The purified protein of claim 387, wherein the protein is fused to a heterologous polypeptide.

398. (New) A composition comprising the purified protein of claim 387 and a pharmaceutically acceptable carrier.

399. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has a wound, tissue, or bone damage.

400. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has ischemia.

401. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has had a myocardial infarction.

402. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

403. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has a wound, tissue, or bone damage.

B1 404. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has ischemia.

405. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has had a myocardial infarction.

406. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein of claim 387, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

---

407. (New) A purified protein fragment produced by the method comprising:

(a) expressing a protein fragment encoded by the cDNA contained in ATCC

Deposit No. 75698 from a host cell, wherein said protein fragment has angiogenic

activity; and

(b) recovering said protein fragment.

408. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a natural source.

409. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

410. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a mammalian cell.

411. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a bacterial cell.

412. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a baculovirus cell.

413. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered from a yeast cell.

414. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered by chromatography.

415. (New) The purified protein fragment of claim 407, wherein the protein fragment is recovered by an antibody.

416. (New) The purified protein fragment of claim 407, wherein the protein fragment is a homodimer.

417. (New) The purified protein fragment of claim 407, wherein the protein fragment is fused to a heterologous polypeptide.

418. (New) A composition comprising the purified protein fragment of claim 407 and a pharmaceutically acceptable carrier.

419. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has a wound, tissue, or bone damage.

420. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has ischemia.

421. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has had a myocardial infarction.

422. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

423. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has a wound, tissue, or bone damage.

424. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has ischemia.

425. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has had a myocardial infarction.

426. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 407, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

13, Sub C  
427. (New) A purified protein fragment produced by the method comprising:

(a) expressing a protein fragment encoded by the cDNA contained in ATCC Deposit No. 75698 from a host cell, wherein said protein fragment has endothelial cell proliferative activity; and

(b) recovering said protein fragment.

428. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a natural source.

429. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a recombinant host cell engineered to express the protein fragment.

430. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a mammalian cell.

431. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a bacterial cell.

432. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a baculovirus cell.

433. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered from a yeast cell.

434. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered by chromatography.

435. (New) The purified protein fragment of claim 427, wherein the protein fragment is recovered by an antibody.

436. (New) The purified protein fragment of claim 427, wherein the protein fragment is a homodimer.

B, 437. (New) The purified protein fragment of claim 427, wherein the protein fragment is fused to a heterologous polypeptide.

438. (New) A composition comprising the purified protein fragment of claim 427 and a pharmaceutically acceptable carrier.

439. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has a wound, tissue, or bone damage.

440. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has ischemia.

441. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has had a myocardial infarction.

442. (New) A method of stimulating proliferation of endothelial cells in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.

B<sub>1</sub> 443. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has a wound, tissue, or bone damage.

444. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has ischemia.

445. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has had a myocardial infarction.

446. (New) A method of stimulating angiogenesis in a patient comprising administering to the patient the purified protein fragment of claim 427, wherein the patient has coronary artery disease, peripheral vascular disease, or CNS vascular disease.--

---